How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market
1. BDRX advances eRapa treatment for Familial Adenomatous Polyposis (FAP). 2. FDA granted eRapa Fast Track and Orphan Drug status. 3. Phase 3 Serenta trial underway in U.S. and Europe. 4. eRapa targets $7 billion market opportunity if approved. 5. Biodexa aims to replicate success similar to Palvella Therapeutics.